Four operational 4X layers, with release controls face up.
4X Essential is our defined standard for identity, purity, net content, and required Rapid DNA. Axiom owns and operates the required methods, so paid samples are accepted, accessioned, and queued. USP <71> is a separate culture upgrade with no less than 14 days of incubation and an additional sealed-container allocation. Below: what each check answers, its method status, and the evidence gates that control final report release.
What we recommend, and why
4X Essential
$195The standard every compound should actually meet.
4X requires identity, chromatographic purity, net content, and Rapid Microbial DNA at Layer 4. Paid intake, observation entry, signing, and release remain open; unresolved Rapid platform, control, peptide-matrix, criterion, or material evidence prevents PASS and creates a finding surfaced to our staff for resolution. USP <71> remains a separate upgrade.
8X Comprehensive
$595Extra depth for peace of mind - not because you need it.
8X adds endotoxin, heavy metals, post-reconstitution stability, and a fentanyl/analog adulterant screen. Worth it when you want maximum assurance or are vetting a brand-new source - but we will not pretend a clean 4X result is somehow incomplete.
Most labs upsell a higher “X” as if more layers automatically means a safer vial. That is a marketing gimmick. Both current panel definitions require identity, chromatographic purity, net content, and Rapid DNA; USP <71> is a separate culture upgrade. Both accept paid samples under controlled accession, while unresolved evidence remains face up, prevents PASS, and is surfaced to our staff for resolution.
The three base determinations
Operational for paid intakeEach answers one specific question. Samples are accepted against the ordered scope; result entry keeps protocol-defined expected values, acceptance ranges, units, and sources face up and locked. Only analysts and instruments supply observations. Incomplete run evidence is surfaced to our staff for resolution without closing entry, signing, or release.
Identity
LC-MS/MS (ESI+)LC-MS/MS confirms exact monoisotopic mass and fragmentation identity, ±1 Da. Identity consistent with expected mass.
Purity
RP-HPLC 214nm (USP 621)RP-HPLC at 214nm isolates the main peak from related substances at the peptide-bond absorbance wavelength.
Net Peptide Content
Quantitative HPLC vs reference stdQuantitative HPLC against a qualified reference standard, stripping moisture, salts, and counter-ions like TFA. Reported as mg per vial.
Rapid DNA is the required fourth 4X layer and is a research target-DNA screen, not viable CFU enumeration, USP <61>, or USP <71>. It is accepted and queued as its own ordered method. USP <71> remains a separately selected two-media culture service with no less than 14 days of incubation and its own material, suitability, media-control, execution, and release evidence.
Sterility (Rapid PCR)
Qualification-bound DNA molecular research screenQualification-pending DNA molecular-screen path. It may be ordered, accessioned, observed, signed, and released; unresolved method source, platform threshold, controls, or material budget prevent PASS and create a finding surfaced to our staff for resolution. It is neither USP <61> enumeration nor USP <71> sterility, and DNA signal is not viable CFU.
The four expanded checks
Added by 8X ComprehensiveBelt-and-suspenders depth: endotoxin, heavy metals, post-reconstitution stability, and a fentanyl/analog adulterant screen. Worth it for maximum assurance or a brand-new source, not because a clean 4X result is incomplete.
Endotoxin
Kinetic chromogenic LALKinetic chromogenic LAL (USP 85). Reported in EU/mL and EU/mg against a stated limit.
Heavy Metals
ICP-MS (USP 232/233)ICP-MS (USP 232/233) for Pb, As, Cd, Hg at sub-ppb. Each element: result, unit, LOQ, and specification source.
Stability
Forced-degradation stabilityPost-reconstitution pH, clarity, and 24h forced-degradation kinetics on the submitted analytical article. Cross-vial consistency is a separate optional service, not part of Layer 7.
Fentanyl Screen
LC-MS/MS targeted adulterant screenLC-MS/MS targeted screen for fentanyl and common analogs (acetylfentanyl, carfentanil, and others). A harm-reduction adulterant check reported as detected / not-detected against a method detection limit.
Methods & validation status
Each row is one of the eight operational layers above. Method status describes how a determination may be represented on a released record; it does not prevent sample custody. Expected criteria and sources are frozen face up, actual observations remain analyst/instrument-entered, and incomplete evidence is surfaced to our staff for resolution while the COA remains signable and releasable.
Method validated by Axiom for the stated analyte, matrix, and range.
An established compendial procedure (e.g. USP) verified as suitable for use.
A research-screen or qualification-held method. Paid accession, observation entry, signing, and release remain available, but absent reopenable signed evidence prevents PASS and creates a finding surfaced to our staff for resolution.
| Layer · Method | Reference | Instrument | Status | Range | LOQ |
|---|---|---|---|---|---|
| 01Identity | Intact mass + MS/MS · qualification target | LC-MS/MS (tandem quadrupole); LC/MS (single quadrupole) | Research / qualification-held | PROPOSED · ±1 Da | Not qualified |
| 02Purity | USP <621> framework · exact method pending | RP-HPLC with diode-array detection | Research / qualification-held | Not qualified | Not qualified |
| 03Net Peptide Content | Quantitative HPLC vs reference standard · qualification target | RP-HPLC with diode-array detection | Research / qualification-held | Not qualified | Not qualified |
| 04Sterility (Rapid PCR) | Qualification-bound molecular target screen (not USP 61 or USP 71) | Candidate evidence under qualification | Research / qualification-held | NOT CONFIGURED · STAFF RESOLUTION | Matrix-specific signed threshold required |
| 05Endotoxin | USP <85> framework · exact matrix suitability pending | Controlled equipment binding not configured | Research / qualification-held | Not qualified | Not qualified |
| 06Heavy Metals | USP <232>/<233> framework · exact method pending | ICP-MS (triple quadrupole) | Research / qualification-held | Not qualified | Not qualified |
| 07Stability | Post-reconstitution kinetics · research target | Controlled equipment binding not configured | Research / qualification-held | Not qualified | Not qualified |
| 08Fentanyl Screen | Targeted LC-MS/MS adulterant screen · research target | Controlled equipment binding not configured | Research / qualification-held | Not qualified | Not qualified |
Axiom Analytics does not currently hold ISO/IEC 17025 accreditation in its own right. Physical instrument analysis is performed within Axiom's laboratory network, and where analysis is subcontracted the method is performed within that partner laboratory's published ISO/IEC 17025 scope of accreditation for that method, not merely at a laboratory that holds accreditation. Partner laboratory identities are not disclosed: samples are analysed under double-blind conditions, identified only by an internal lot ID. Axiom performs accession, chain of custody, analytical oversight and data review, and issues and is responsible for the certificate. The platform identifies method status beside each result; absent reopenable signed method/QMS evidence prevents PASS and creates a finding surfaced to our staff for resolution without closing controlled accession, observation entry, signing, or release. Software controls are not a substitute for physical laboratory qualification.
What we test, and what we do not
Our catalog accepts peptides, exact oral tablets and capsules, and declared aqueous, oil, or other supported presentations. Product-specific methods and criteria still govern release. Schedule III requests may be saved, but do not ship until the submitting account's authorization is verified.
ACCEPTED
| Category | Examples | Accepted form |
|---|---|---|
| Peptides | BPC-157, semaglutide, tirzepatide, CJC-1295, ipamorelin, TB-500, KPV, and blends of them | Lyophilized powder, aqueous solution, cartridge |
| Peptide blends | Any combination of the peptides above A blend is certified per component. An area percent across a blend is not a purity figure for any one of them. | Lyophilized powder, aqueous solution |
| Peptide hydrolysates | Cerebrolysin, cerebroprotein hydrolysate These are defined mixtures, not single molecules, so the certificate carries a molecular-weight distribution and a composition profile instead of an accurate mass and a purity percent. Tell us which preparation you sent: Cerebrolysin and the generic cerebroprotein hydrolysates have different peptide profiles, and a result from one says nothing about the other. | Lyophilized powder, aqueous solution |
| Amino acids | L-arginine, L-citrulline, L-methionine, L-ornithine These respond weakly at our purity wavelength, so quantitation is by mass rather than by area percent. | Lyophilized powder, aqueous solution |
| Small molecules with a real chromophore | 5-Amino-1MQ, AICAR, SLU-PP-332, thiamine, pyridoxine, methylene blue | Lyophilized powder, aqueous or oil solution, capsule, tablet |
| Catalog oral products | Exact supplier-listed tablets and capsules, including catalog SARMs and ancillary small molecules Intake is conditional on the exact SKU. PASS requires product-specific reference material, method fit, source-backed criteria, and the submitted strength; while any item is unresolved, the finding is surfaced to our staff for resolution without blocking submission, entry, signing, or release. A peptide panel is never substituted for an oral small-molecule method. | Tablet, capsule |
| Oil and other non-aqueous preparations | Exact catalog injection presentations whose vehicle is declared as oil or another non-aqueous carrier Vehicle identity is not inferred from a supplier section heading. Unknown carrier composition is surfaced to our staff for resolution without blocking entry, signing, or release. Schedule III articles separately require verified customer authorization before shipping or custody. | Solution or suspension; vehicle recorded separately as oil, aqueous, mixed, or unknown |
| Vitamins and cofactors | Methylcobalamin and cyanocobalamin (B12), NAD+ B12 is photolabile, and the cyano and methyl forms are distinct molecules. Tell us which one you sent. | Lyophilized powder, aqueous solution |
| Polar small molecules | L-carnitine, choline chloride, myo-inositol These are invisible to a reverse-phase purity method and are quantified on a separate lane. | Lyophilized powder, aqueous solution |
| Copper peptide complexes | GHK-Cu, AHK-Cu The copper is not held by a covalent bond and our standard purity lane strips it. These are quantified on a method that leaves the complex intact, and the copper content is reported separately. | Lyophilized powder, aqueous solution |
CONDITIONAL INTAKE
These are not judgements about the products. Declined categories lack a defensible current testing route; conditional categories remain selectable while their exact authorization, presentation, method, or criteria are resolved.
Schedule III testing is conditionally available. You may select and save the exact product now, but Axiom will not release a shipping address, accept custody, or begin work until the submitting company or account has a current verified authorization for the registered location and schedule.
Catalog tablets, capsules, and related small molecules may enter conditional testing. PASS requires the exact analyte, presentation, matched reference standard, method, and face-up acceptance criteria; while any item is unresolved, the finding is surfaced to our staff for resolution without blocking submission, entry, signing, or release. A peptide method is never substituted just because it is on the bench.
Oil vehicles are supported as a separate controlled presentation. Declare the vehicle exactly. PASS requires oil-specific preparation, method suitability, reference material, and acceptance criteria; while any item is unresolved, the finding is surfaced to our staff for resolution without blocking submission, entry, signing, or release.
Exact products already present in the controlled catalog may enter conditional testing. Unlisted finished drug products require a method-and-authority preflight; no peptide panel, generic product family, or customer label substitutes for product-specific criteria.
You may select and save an exact Schedule III catalog product. Axiom does not release shipping instructions, accept custody, or begin analysis until the submitting company or account has a current verified authorization for the registered location and Schedule III activity. The credential and its evidence remain private; the order stores only a masked verification snapshot.
NOT ACCEPTED
Cannabinoid potency is a different method on a different matrix, and it is separately regulated at state level. We do not offer it.
An extract has no single molecular identity, so there is no accurate mass to confirm and an area percent would not mean what it appears to mean.
Accreditation status, stated plainly
No decorative badges, no claims beyond the evidence. Here is the quality system behind every result, and exactly where we stand on accreditation.
Controlled QMS evidence
Reopenable SOP, chain-of-custody, equipment-qualification, and retest-policy artifacts support conformance. Missing or unqualified artifacts become findings surfaced to our staff for resolution without closing accession, entry, signing, or release.
Method Qualification
Before activation, the signed record must state analyte, matrix, range, specificity, precision, accuracy, quantitation limit, controls, approval, and revision.
Reference Standards
Qualified reference-material lots, recorded blanks, controls, and suitability checks remain face up. Missing records become findings surfaced to our staff for resolution; the software never fabricates them.
Independent Review
Analyst and technical-review attribution remains explicit. Missing physical review evidence is recorded for administrator review and is never inferred or fabricated.
Correction Policy
Amendments create a new version; prior versions are superseded but retained. Full revision history is public on verify.
Zero Conflicts
Axiom owns zero retail brands and zero inventory. We are strictly a data-verification laboratory.
Plan with 4X. Add 8X only when you want the extra depth.
Paid 4X Essential and 8X Comprehensive intake is open. Normal work targets 6 business days average from receipt (48-hour 4X rush; 72-hour 8X rush). USP <71> is separate, requires its additional container allocation, and carries no less than 14 days of incubation.